Ratan Tata, Chairman of the multibillion-dollar global conglomerate Tata Group has joined the global advisory board of Nanobiosym, a leading nanotechnology firm.

Nanobiosym and its commercial engine, Nanobiosym Diagnostics create and commercialize breakthrough technologies at the nexus of physics, biomedicine, and nanotechnology.

Dr Anita Goel, a Harvard and MIT-trained physicist and physician said that it was an honour to welcome Tata to its global advisory board. She went on to say that she was inspired by his example, providing the company with a practical roadmap for bringing cutting edge technologies into emerging global economies and extending its reach to broad markets at the 'bottom of the pyramid'.

Nanobiosym had developed Gene-RADAR, a portable nanotechnology platform that rapidly and accurately detected genetic fingerprints from any biological organism. Dr Goel's vision was to give patients worldwide real-time access to their own diagnostic information through low-cost handheld devices that could detect disease from a single drop of blood or saliva.

According to Tata, Nanotechnology has the potential to revolutionize the way key issues are tackled, facing the world today and Nanobiosym was working at the forefront of this revolution. Dr Goel had forged a bold model for driving technological innovation and commercialization, while maximizing global humanitarian impact. He said that he was delighted to join the Nanobiosym's global advisory board, and looked forward to working closely with Dr Goel and her team.

Alfred Ford, Director of the Ford Motor Company Fund and also a member of the Nanobiosym global advisory board, commented that behind the company's vision of its game-changing technology which could revolutionize healthcare globally. In the face of growing world health crises and transnational epidemics, Dr Goel and Nanobiosym were redefining the rules in the battle to diagnose disease and save lives.